Pfizer, GSK settle patent lawsuit over RSV vaccines
Pfizer (NYSE:PFE) and GSK (NYSE:GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, ...
Zacks.com on MSN2d
PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo
The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of ...
Fierce Pharma19h
GSK, Pfizer resolve RSV patent feud amid vaccine market uncertainty
As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
EconoTimes23h
GSK and Pfizer Drop RSV Vaccine Patent Lawsuit
GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
Pfizer announces European Commission approval of Abrysvo indication extension
Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...
Pfizer reports EC approval of amending marketing authorization of Abrysvo
Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...
Medical Dialogues2d
Pfizer Abrysvo gets European Commission nod for RSV Lower Respiratory Tract Disease in adults aged 18-59 years
Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ...
Pfizer Gets Expanded European Approval of Abrysvo RSV Vaccine for All Adults
Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...
GSK resolves patent lawsuit against Pfizer over RSV vaccines
By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...
Seeking Alpha4d
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...